Antibody-drug Conjugates in Cancer Treatment: An Overview

References (54)

1. 1 Continuous cultures of fused cells secreting antibody of predefined specificity [DOI]
2. 2 Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo [DOI]
3. 3 Phage antibodies: filamentous phage displaying antibody variable domains [DOI]
4. 4 Strategies and challenges for the next generation of antibody–drug conjugates [DOI]
5. 5 Antibody drug conjugate: the “biological missile” for targeted cancer therapy [DOI]
6. 6 Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia [DOI]
7. 7 Unlocking the potential of antibody–drug conjugates for cancer therapy [DOI]
8. 8 Potent antibody therapeutics by design [DOI]
9. 9 Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. [DOI]
10. 10 Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse [DOI]
11. 11 Neu-Protein Overexpression in Breast Cancer [DOI]
12. 12 Antibody-drug conjugates: recent advances in conjugation and linker chemistries [DOI]
13. 13 A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal Transplants [DOI]
14. 14 Site-specific antibody drug conjugates for cancer therapy [DOI]
15. 15 Gemtuzumab Ozogamicin, A Potent and Selective Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia [DOI]
16. 16 Antibody–drug conjugates: current status and future directions [DOI]
17. 17 Antibody-Drug Conjugate-Based Therapeutics: State of the Science [DOI]
18. 18 Potent antibody drug conjugates for cancer therapy [DOI]
19. 19 Antibody–Drug Conjugates for Cancer Therapy [DOI]
20. 20 Waste disposal—An attractive strategy for cancer therapy [DOI]
21. 21 Trastuzumab Deruxtecan: First Approval [DOI]
22. 22 Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes [DOI]
23. 23 Polatuzumab Vedotin: First Global Approval [DOI]
24. 24 Recent advances of antibody drug conjugates for clinical applications [DOI]
25. 25 Advances in antibody–drug conjugates: A new era of targeted cancer therapy [DOI]
26. 26 Immunotoxins and Anticancer Drug Conjugate Assemblies: The Role of the Linkage between Components [DOI]
27. 27 Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations [DOI]
28. 28 Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy [DOI]
29. 29 The next generation of antibody-drug conjugates comes of age.
30. 30 Vascular targeted therapies in oncology [DOI]
31. 31 Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma [DOI]
32. 32 The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics [DOI]
33. 33 Antibody‐Incorporated Nanomedicines for Cancer Therapy [DOI]
34. 34 Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer [DOI]
35. 35 Immunogenicity of Antibody–drug Conjugates: Observations Across 8 Molecules in 11 Clinical Trials [DOI]
36. 36 The Collected Papers of Paul Ehrlich [DOI]
37. 37 The covalent binding of daunomycin and adriamycin to antibodies, with retention of both drug and antibody activities.
38. 38 Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids [DOI]
39. 39 Antibody–drug conjugates in breast cancer: the chemotherapy of the future? [DOI]
40. 40 The EMA Review of Mylotarg (Gemtuzumab Ozogamicin) for the Treatment of Acute Myeloid Leukemia [DOI]
41. 41 Robo4 is an effective tumor endothelial marker for antibody-drug conjugates based on the rapid isolation of the anti-Robo4 cell-internalizing antibody [DOI]
42. 42 Sacituzumab govitecan: an antibody–drug conjugate [DOI]
43. 43 Conjugates of Small Molecule Drugs with Antibodies and Other Proteins [DOI]
44. 44 ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies [DOI]
45. 45 Suppression of tumour growth in mice by a drug–antibody conjugate using a novel approach to linkage [DOI]
46. 46 Antibody as carrier of chlorambucil [DOI]
47. 47 Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas [DOI]
48. 48 Coupling of Cyclic Chemotherapeutic Compounds to Immune Gamma-Globulins [DOI]
49. 49 Suppression of an AKR Lymphoma by Antibody and Chlorambucil2 [DOI]
50. 50 Approaches to the immunological treatment of cancer in man. [DOI]
51. 51 A comprehensive review of key factors affecting the efficacy of antibody drug conjugate [DOI]
52. 52 Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs [DOI]
53. 53 On-Target Side Effects of Targeted Therapeutics of Cancer [DOI]
54. 54 A REVIEW ARTICLE ON THE NOVEL MECHANISMS FOR DELIVERY OF CANCER THERAPEUTICS [DOI]

Cited by 6

Showing 3 of 6 known citations — external sources report more than can currently be individually listed.

Related research

• Accessibility and Inclusivity of Chimeric Antigen Receptor T-cell Immunotherapy in Treating Hematological Malignancies — shares topic coverage
• Oncology Nurses’ Knowledge of Chemotherapy Administration in a Tertiary Centre in Ghana: A Qualitative Study — shares topic coverage
• Emergent New Anti PD-1/PD-L1 Small Molecules for Cancer Treatment — shares topic coverage
• Lived Experiences of Sexuality among Women Undergoing Breast Cancer Treatment at a Major Cancer Center in Ghana — shares topic coverage
• Targeted and Immunotherapeutic Approaches in Cancer: A Narrative Review of Evolving Evidence and Clinical Implications — shares topic coverage